{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T15:20:33Z","timestamp":1771082433737,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,3,3]],"date-time":"2018-03-03T00:00:00Z","timestamp":1520035200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s40273-018-0624-7","type":"journal-article","created":{"date-parts":[[2018,3,3]],"date-time":"2018-03-03T04:04:47Z","timestamp":1520049887000},"page":"759-768","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3099-9877","authenticated-orcid":false,"given":"Matt","family":"Stevenson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Pandor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clare","family":"Rowntree","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marrissa","family":"Martyn-St James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Rawdin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,3]]},"reference":[{"key":"624_CR1","unstructured":"National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2013\u2014process and methods [PMG9]. London: NICE. 2013. https:\/\/www.nice.org.uk\/article\/pmg9\/ . Accessed 23 November 2016."},{"key":"624_CR2","unstructured":"Pandor A, Stevenson M, Martyn-St James M, Stevens J, Hamilton J, Rawdin A et al. Ponatinib for treating acute lymphoblastic leukaemia: a single technology appraisal. School of Health and Related Research (ScHARR). 2016. https:\/\/www.nice.org.uk\/guidance\/ta451\/documents\/committee-papers . Accessed 20 Nov 2017."},{"key":"624_CR3","unstructured":"National Institute for Health and Care Excellence. Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia. Final Scope. National Institute for Health and Care Excellence (NICE), London. 2016. https:\/\/www.nice.org.uk\/guidance\/ta451\/documents\/committee-papers . Accessed 20 Nov 2017."},{"issue":"7","key":"624_CR4","doi-asserted-by":"publisher","first-page":"858","DOI":"10.6004\/jnccn.2012.0089","volume":"10","author":"JC Alvarnas","year":"2012","unstructured":"Alvarnas JC, Brown PA, Aoun P, Ballen KK, Bellam N, Blum W, et al. Acute lymphoblastic leukemia. J Natl Compr Canc Netw. 2012;10(7):858\u2013914.","journal-title":"J Natl Compr Canc Netw."},{"key":"624_CR5","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia. Version 1.0. 2016. https:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp . Accessed 23 Nov 2016."},{"issue":"1","key":"624_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0889-8588(05)70198-2","volume":"15","author":"JP Radich","year":"2001","unstructured":"Radich JP. Philadelphia chromosome-positive acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2001;15(1):21\u201336.","journal-title":"Hematol Oncol Clin North Am."},{"key":"624_CR7","unstructured":"European Medicines Agency (EMA). Assessment Report for Inclusig\u00ae (ponatinib). Procedure No EMEA\/H\/C\/002695\/0000. London: EMA. 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002695\/WC500145648.pdf . Accessed 23 November 2017."},{"issue":"3","key":"624_CR8","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","volume":"109","author":"AK Fielding","year":"2007","unstructured":"Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study. Blood. 2007;109(3):944\u201350.","journal-title":"Blood."},{"key":"624_CR9","doi-asserted-by":"crossref","unstructured":"Fielding AK. Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program 2011:231\u20137.","DOI":"10.1182\/asheducation-2011.1.231"},{"key":"624_CR10","unstructured":"Public Health England. National Cancer Intelligence Network Trends in incidence and outcome for haematological cancers in England: 2001\u20132010. London: Public Health England. 2015. http:\/\/www.ncin.org.uk\/view?rid=2818 . Accessed 20 November 2017."},{"issue":"2","key":"624_CR11","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.clml.2011.03.002","volume":"11","author":"F Ravandi","year":"2011","unstructured":"Ravandi F. Managing Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors. Clin Lymphoma Myeloma Leuk. 2011;11(2):198\u2013203.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"624_CR12","unstructured":"Novartis Europharm Limited. Glivec\u00ae (imatinib) 50-mg and 100-mg hard capsules and 100-mg and 400-mg film-coated tablets: Summary of Product Characteristics. [updated 28 November 2016]. 2016. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000406\/WC500022207.pdf . Accessed 1 Dec 2016."},{"key":"624_CR13","unstructured":"Bristol-Myers Squibb Pharma. Sprycel\u00ae (dasatinib) 20-mg, 50-mg, 70-mg, 80-mg, 100-mg, 140-mg film-coated tablets: Summary of Product Characteristics. [updated 20 July 2016]. 2016. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000709\/WC500056998.pdf . Accessed 1 Dec 2016."},{"key":"624_CR14","unstructured":"ARIAD Pharma Ltd. Iclusig\u00ae (ponatinib) 15-mg, 30-mg, and 45-mg film-coated tablets: summary of product characteristics. [updated 16 September 2016]. 2016. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002695\/WC500145646.pdf . Accessed 1 Dec 2016."},{"key":"624_CR15","unstructured":"Adcock A, Powell T. Removal of drugs from Cancer Drugs Fund list. London: House of Commons Library. 2016. http:\/\/researchbriefings.parliament.uk\/ResearchBriefing\/Summary\/CDP-2016-0009 . Accessed 1 Dec 2016."},{"key":"624_CR16","unstructured":"Incyte Corporation. Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia [ID671]. Response to clarification letter. 2016. https:\/\/www.nice.org.uk\/guidance\/ta451\/documents\/committee-papers . Accessed 22 Nov 2017."},{"issue":"22","key":"624_CR17","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","volume":"367","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012;367(22):2075\u201388. https:\/\/doi.org\/10.1056\/NEJMoa1205127 .","journal-title":"N Engl J Med."},{"key":"624_CR18","doi-asserted-by":"crossref","unstructured":"Talpaz M, Cortes JE, Kantarjian HM, Shah NP, Bixby DL, Flinn I et al. Four-year minimum follow-up of ongoing patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) in a phase 1 trial of ponatinib (PON). J Clin Oncol (Meeting Abstracts). 2015;33(15_suppl):7047.","DOI":"10.1200\/jco.2015.33.15_suppl.7047"},{"issue":"19","key":"624_CR19","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim D-W, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783\u201396. https:\/\/doi.org\/10.1056\/NEJMoa1306494 .","journal-title":"N Engl J Med"},{"issue":"S1","key":"624_CR20","first-page":"64","volume":"100","author":"JE Cortes","year":"2015","unstructured":"Cortes JE, Kim D-W, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. Ponatinib efficacy and safety in heavily pretreated leukemia patients: 3-Year results of the pace trial. P234. Haematologica. 2015;100(S1):64.","journal-title":"Haematologica."},{"issue":"23","key":"624_CR21","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1182\/blood.V126.23.4025.4025","volume":"126","author":"A Hochhaus","year":"2015","unstructured":"Hochhaus A, Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, et al. Efficacy and safety of ponatinib in CP-CML patients by number of prior tyrosine kinase inhibitors: 4-year follow-up of the phase 2 PACE trial. Blood. 2015;126(23):4025.","journal-title":"Blood."},{"key":"624_CR22","unstructured":"U.S. Food and Drug Administration Center for Drug Evaluation and Research. Application number: 203469Orig1s000 Medical review. 2012. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203469Orig1s000MedR.pdf . Accessed 23 Nov 2016."},{"issue":"12","key":"624_CR23","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.jclinepi.2008.12.010","volume":"62","author":"D Chambers","year":"2009","unstructured":"Chambers D, Rodgers M, Woolacott N. Not only randomized controlled trials, but also case series should be considered in systematic reviews of rapidly developing technologies. J Clin Epidemiol. 2009;62(12):1253\u201360. https:\/\/doi.org\/10.1016\/j.jclinepi.2008.12.010 .","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"624_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.6030\/1939-067X-3.1.8","volume":"3","author":"S Evans","year":"2010","unstructured":"Evans S. Clinical trial structures. J Exp Stroke Transl Med. 2010;3(1):8\u201318.","journal-title":"J Exp Stroke Transl Med."},{"issue":"9","key":"624_CR25","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1038\/sj.leu.2404824","volume":"21","author":"E Tavernier","year":"2007","unstructured":"Tavernier E, Boiron JM, Huguet F, Bradstock K, Vey N, Kovacsovics T, et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia. 2007;21(9):1907\u201314. https:\/\/doi.org\/10.1038\/sj.leu.2404824 .","journal-title":"Leukemia."},{"issue":"12","key":"624_CR26","first-page":"1327","volume":"85","author":"L Pagano","year":"2000","unstructured":"Pagano L, Mele L, Casorelli I, Fianchi L, Di Febo A, Leone G. Acute lymphoblastic leukemia in the elderly. A twelve-year retrospective, single center study. Haematologica. 2000;85(12):1327\u20139.","journal-title":"Haematologica."},{"issue":"1","key":"624_CR27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1524-4733.2009.00573.x","volume":"13","author":"SM Szabo","year":"2010","unstructured":"Szabo SM, Levy AR, Davis C, Holyoake TL, Cortes J. A multinational study of health state preference values associated with chronic myelogenous leukemia. Val Health. 2010;13(1):103\u201311. https:\/\/doi.org\/10.1111\/j.1524-4733.2009.00573.x .","journal-title":"Val Health"},{"key":"624_CR28","unstructured":"Kind P, Hardman G, Macran S. UK population norms for EQ-5D. 1999. http:\/\/EconPapers.repec.org\/RePEc:chy:respap:172chedp . Accessed 1 Dec 2016."},{"key":"624_CR29","doi-asserted-by":"crossref","unstructured":"van Agthoven M, Vellenga E, Fibbe WE, Kingma T, Uyl-de Groot CA. Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin\u2019s lymphoma or Hodgkin\u2019s disease. a prospective randomised trial. Eur J Cancer (Oxford, England: 1990). 2001;37(14):1781\u20139.","DOI":"10.1016\/S0959-8049(01)00198-8"},{"key":"624_CR30","doi-asserted-by":"publisher","unstructured":"Loveman E, Cooper K, Bryant J, Colquitt JL, Frampton GK, Clegg A. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation. Health Technol Assess (Winchester, England). 2012;16(23):iii\u2013xiii, 1\u2013137. https:\/\/doi.org\/10.3310\/hta16230 .","DOI":"10.3310\/hta16230"},{"key":"624_CR31","unstructured":"UK Stem Cell Strategy Oversight Committee. NHS Blood and Transplant. Unrelated Donor Stem Cell Transplantation in the UK. Effective Affordable Sustainable. 2014. http:\/\/www.nhsbt.nhs.uk\/download\/unrelated_donor_stem_cell_transplantation_in_the_uk.pdf . Accessed 1 Dec 2016."},{"key":"624_CR32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan\u2013Meier survival curves. BMC Med Res Methodol. 2012;12:9. https:\/\/doi.org\/10.1186\/1471-2288-12-9 .","journal-title":"BMC Med Res Methodol."},{"issue":"430","key":"624_CR33","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1080\/01621459.1995.10476572","volume":"90","author":"RE Kass","year":"1995","unstructured":"Kass RE, Raftery AE. Bayes factors. J Am Stat Assoc. 1995;90(430):773\u201395. https:\/\/doi.org\/10.2307\/2291091 .","journal-title":"J Am Stat Assoc"},{"key":"624_CR34","unstructured":"National Institute for Health and Care Excellence (NICE). Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia\u2014technology appraisal guidance [TA451]. NICE, London. 2017. https:\/\/www.nice.org.uk\/guidance\/ta451\/ . Accessed 23 Nov 2017."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-018-0624-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-018-0624-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-018-0624-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T23:14:26Z","timestamp":1603926866000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-018-0624-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,3]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["624"],"URL":"https:\/\/doi.org\/10.1007\/s40273-018-0624-7","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,3]]},"assertion":[{"value":"3 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr Clare Rowntree undertook some consulting work in 2015\u20132016 for ARIAD Pharmaceuticals, the manufacturer of ponatinib. This work resulted in an authored published abstract in a health economics journal. MS, AP, JH, JS, MMSJ, AR, RW have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}